RESUMEN
A new series of 16E-arylidene androstene derivatives has been synthesized and evaluated for aromatase inhibitory activity. The impact of various aryl substituents at 16 position of the steroid skeleton on aromatase inhibitory activity has been observed. The 16E-arylidenosteroids 6, 10 and 11 exhibited significant inhibition of the aromatase enzyme. 16-(4-Pyridylmethylene)-4-androstene-3,17-dione (6, IC(50): 5.2 µM) and 16-(benzo-[1,3]dioxol-5-ylmethylene)androsta-1,4-diene-3,17-dione (11, IC(50): 6.4 µM) were found to be approximately five times more potent in comparison to aminoglutethimide.
Asunto(s)
Inhibidores de la Aromatasa/síntesis química , Aromatasa/química , Esteroides/química , Aminoglutetimida/química , Aminoglutetimida/metabolismo , Aminoglutetimida/farmacología , Androstenos/química , Aromatasa/metabolismo , Inhibidores de la Aromatasa/química , Unión Proteica , Esteroides/síntesis química , Esteroides/metabolismoRESUMEN
Theca-interstitial (T-I) cells of the ovary synthesize androgens in response to luteinizing hormone (LH). In pathological conditions such as polycystic ovarian syndrome, T-I cells are hyperactive in androgen production in response to LH and insulin. Because cholesterol is an essential substrate for androgen production, we examined the effect of human chorionic gonadotropin (hCG) and insulin on signaling pathways that are known to increase cholesterol accumulation in steroidogenic cells. Specifically, the effect of hCG and insulin on sterol regulatory element-binding transcription factor 1a (SREBF1a) required for cholesterol biosynthesis and uptake was examined. Primary cultures of T-I cells isolated from 25-day-old rat ovaries responded to hCG and insulin to increase the active/processed form of SREBF1a. The hCG and insulin significantly reduced insulin-induced gene 1 (INSIG1) protein, a negative regulator of SREBF processing. Furthermore, an increase in the expression of selected SREBF target genes, 3-hydroxy-3-methylglutaryl-coenzyme A reductase (Hmgcr) and mevalonate kinase (Mvk), was also observed. Protein kinase A (PRKA) inhibitor completely abolished the hCG-induced increase in SREBF1a, while increasing INSIG1. Although the hCG-induced depletion of total and free cholesterol was abolished by aminoglutethimide, the stimulatory effect on SREBF1a was not totally suppressed. Treatment with 25-hydroxycholesterol abrogated the effect of hCG on SREBF1a. Inhibition of the phosphatidylinositol 3-kinase pathway did not block the insulin-induced increase in SREBF1a, whereas mitogen-activated protein kinase inhibition reduced the insulin response. These results suggest that the increased androgen biosynthesis by T-I cells in response to hCG and insulin is regulated, at least in part, by increasing the expression of sterol response element-responsive genes by increasing SREBF1a.
Asunto(s)
Gonadotropina Coriónica/fisiología , Insulina/fisiología , Proteína 1 de Unión a los Elementos Reguladores de Esteroles/genética , Células Tecales/metabolismo , Proteínas Quinasas Activadas por AMP/antagonistas & inhibidores , Aminoglutetimida/metabolismo , Análisis de Varianza , Andrógenos/biosíntesis , Androstenodiona/biosíntesis , Animales , Células Cultivadas , Colesterol/metabolismo , Gonadotropina Coriónica/metabolismo , Femenino , Regulación de la Expresión Génica , Hidroxicolesteroles/metabolismo , Hidroximetilglutaril-CoA Reductasas/genética , Hidroximetilglutaril-CoA Reductasas/metabolismo , Insulina/metabolismo , Péptidos y Proteínas de Señalización Intracelular , Proteínas de la Membrana/genética , Proteínas de la Membrana/metabolismo , Proteína Quinasa 1 Activada por Mitógenos/antagonistas & inhibidores , Inhibidores de las Quinasa Fosfoinosítidos-3 , Fosfotransferasas (Aceptor de Grupo Alcohol)/genética , Fosfotransferasas (Aceptor de Grupo Alcohol)/metabolismo , Ratas , Ratas Sprague-Dawley , Esteroide 17-alfa-Hidroxilasa/metabolismo , Proteína 1 de Unión a los Elementos Reguladores de Esteroles/metabolismo , Células Tecales/químicaRESUMEN
BACKGROUND: Studies on peripheral benzodiazepine receptor function have yielded a diverse list of activities of which the anti-inflammatory effects need to be further examined. AIMS: To evaluate the role of steroids, nitric oxide and adenosine-deaminase in the anti-inflammatory effect of PK11195. METHODS: Pleurisy was induced by intrapleural injection of carrageenan in mice pre-treated or not with PK11195. Leukocytes, exudation, adenosine-deaminase (ADA) activity and nitric oxide (NO) level were measured. Steroid involvement was evaluated by pre-treatment with D,L-aminogluthetimide before PK11195. RESULTS: Leukocytes, exudation and NO levels were reduced by PK11195 in the early (4 h) phase. In the late (48 h) phase, PK11195 decreased leukocytes and ADA activity. D,L-aminogluthetimide reversed the effect of PK11195 on exudate (4 h), as well as total and differential leukocytes and NO levels (48 h). CONCLUSIONS: Steroids, NO and ADA are implicated in the anti-inflammatory action of PK11195.
Asunto(s)
Antiinflamatorios/uso terapéutico , Antineoplásicos/uso terapéutico , Isoquinolinas/uso terapéutico , Pleuresia/tratamiento farmacológico , Esteroides/uso terapéutico , Adenosina Desaminasa/metabolismo , Aminoglutetimida/metabolismo , Aminoglutetimida/farmacología , Animales , Antiinflamatorios/metabolismo , Antiinflamatorios/farmacología , Antineoplásicos/metabolismo , Antineoplásicos/farmacología , Carragenina/administración & dosificación , Modelos Animales de Enfermedad , Femenino , Agonistas de Receptores de GABA-A , Isoquinolinas/metabolismo , Isoquinolinas/farmacología , Leucocitos/efectos de los fármacos , Leucocitos/metabolismo , Masculino , Ratones , Nitratos/metabolismo , Óxido Nítrico/metabolismo , Nitritos/metabolismo , Pleuresia/inducido químicamente , Pleuresia/inmunología , Receptores de GABA-A/inmunologíaRESUMEN
Anandamide (AEA), a prominent member of the endogenous ligands of cannabinoid receptors (endocannabinoids), is known to adversely affect female fertility. However, a potential role of AEA in male reproductive functions is unknown. Here we report evidence that immature mouse Sertoli cells have the biochemical tools to bind and inactivate AEA, i.e. a functional type-2 cannabinoid receptor (CB2R), a selective AEA membrane transporter, and an AEA-degrading enzyme fatty acid amide hydrolase. We show that, unlike CB2R, the activity of AEA membrane transporter and the activity and expression of FAAH decrease, whereas the apoptosis-inducing activity of AEA increases with age during the neonatal period. We also show that FSH reduces the apoptotic potential of AEA, but not that of its nonhydrolyzable analog methanandamide. Concomitantly, FSH enhances FAAH activity in a manner dependent on mRNA transcription and protein synthesis and apparently involving cAMP. These data demonstrate that Sertoli cells partake in the peripheral endocannabinoid system, and that FSH reduces the apoptotic potential of AEA by activating FAAH. Taken together, it can be suggested that the endocannabinoid network plays a role in the hormonal regulation of male fertility.
Asunto(s)
Envejecimiento , Grupos de Población Animal/metabolismo , Ácidos Araquidónicos/metabolismo , Hormona Folículo Estimulante/farmacología , Células de Sertoli/metabolismo , Amidohidrolasas/análisis , Amidohidrolasas/genética , Amidohidrolasas/metabolismo , Aminoglutetimida/metabolismo , Grupos de Población Animal/crecimiento & desarrollo , Animales , Apoptosis/efectos de los fármacos , Western Blotting , Química Encefálica , Moduladores de Receptores de Cannabinoides , Membrana Celular/metabolismo , AMP Cíclico/fisiología , Fragmentación del ADN , Endocannabinoides , Ensayo de Inmunoadsorción Enzimática , Fertilidad , Cinética , Masculino , Ratones , Alcamidas Poliinsaturadas , ARN Mensajero/análisis , Receptores de Cannabinoides , Receptores de Droga/análisis , Receptores de Droga/antagonistas & inhibidores , Receptores de Droga/metabolismo , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa , Células de Sertoli/efectos de los fármacos , Células de Sertoli/enzimología , TritioRESUMEN
An accurate and specific liquid chromatographic method for the separation and analysis of the R(+) and S(-) enantiomers of both aminoglutethimide (AG) and its acetylated metabolite (AcAG) in plasma, saliva, and urine is described. The separation was achieved by use of two serial Chiralcel OD columns [cellulose tris(3,5-dimethylphenyl carbamate)] with a mixture of hexane/isopropanol/methanol (65:17.5:17.5, per volume) as a mobile phase. The flow rate was 0.7 ml/min, and the compounds were detected in the effluent spectrophotometrically at 245 nm. The plasma, saliva, or urine sample (300 microliters) was extracted with dichloromethane after the addition of an equal volume of acetate buffer (pH 5.6) to the sample. The extraction recovery of the R(+) and S(-) enantiomers of AG and AcAG from plasma, saliva, and urine at different concentrations under these conditions was > 80.9%. No interference from any endogenous substance or concomitantly used drug was observed. The ratio of the peak area of R(+) and S(-) enantiomers of both AG and AcAG/internal standard was linearly (r > or = 0.995) related to concentration in the range 0.83-40.0 micrograms/ml, and the coefficient of variation (CV) at different concentrations was consistently < or = 13%. We are presently employing this method to study the pharmacokinetics of each of these enantiomers in breast cancer patients.
Asunto(s)
Aminoglutetimida/análogos & derivados , Aminoglutetimida/análisis , Antineoplásicos Hormonales/análisis , 1-Propanol/química , Acetilación , Aminoglutetimida/sangre , Aminoglutetimida/metabolismo , Aminoglutetimida/uso terapéutico , Aminoglutetimida/orina , Antineoplásicos Hormonales/sangre , Antineoplásicos Hormonales/metabolismo , Antineoplásicos Hormonales/uso terapéutico , Antineoplásicos Hormonales/orina , Neoplasias de la Mama/tratamiento farmacológico , Cromatografía Líquida de Alta Presión , Femenino , Hexanos/química , Humanos , Concentración de Iones de Hidrógeno , Metanol/química , Receptores de Estrógenos/efectos de los fármacos , Receptores de Estrógenos/metabolismo , Estándares de Referencia , Reproducibilidad de los Resultados , Saliva/química , Saliva/metabolismo , EstereoisomerismoRESUMEN
1-Pentyl, 1-hexyl and 1-heptyl-3-(4-aminophenyl)pyrrolidine-2,5-dione, potent inhibitors of aromatase, lower oestrogen levels in PMSG-stimulated female rats in a comparable manner to the inhibitor aminoglutethimide (AG) used clinically for the treatment of breast cancer. Pharmacokinetic studies in the rat show t 1/2 values for the 1-hexyl compound and AG of 1.8 and 5.5 h respectively. In 4 tests for CNS-depressant activity the overall order of activity was AG > 1-heptyl = 1- hexyl >> 1-pentyl. The 1-pentyl compound has less tendency than AG to depress white cell and platelet counts in mice and overall is the drug candidate for further studies.
Asunto(s)
Inhibidores de la Aromatasa , Pirrolidinonas/farmacología , Aminoglutetimida/metabolismo , Animales , Sistema Nervioso Central/efectos de los fármacos , Femenino , Ratones , Actividad Motora/efectos de los fármacos , RatasRESUMEN
Prostaglandin F2 alpha (PGF2 alpha) inhibits lipoprotein-stimulated progesterone production by bovine luteal cells in vitro and the objective of this study was to localize the site of action of PGF2 alpha. Cultured bovine luteal cells were treated with PGF2 alpha for seven days, and then with either lipoproteins or 25-hydroxycholesterol in the presence of aminoglutethimide (which inhibits cholesterol side-chain cleavage) for the final 48 h. The effects of PGF2 alpha on progesterone production, cellular cholesterol content, mitochondrial cholesterol content and cholesterol side-chain cleavage activity were determined. As expected, PGF2 alpha inhibited (P less than 0.05) lipoprotein-stimulated progesterone production. However, PGF2 alpha did not inhibit low-density lipoprotein-stimulated, or high density lipoprotein-stimulated, increases in cellular cholesterol (P less than 0.05) or inhibit lipoprotein-induced increases in mitochondrial cholesterol content (P less than 0.05). Additionally, cholesterol content of mitochondria increased (P less than 0.05) in the presence of PGF2 alpha alone. To determine if the PGF2 alpha-induced inhibition of steroidogenesis occurred at, or after, the side-chain cleavage reaction, we treated cells with the readily diffusable sterol, 25-hydroxycholesterol. Prostaglandin F2 alpha did not inhibit 25-hydroxycholesterol-stimulated progesterone production (P less than 0.05). Prostaglandin F2 alpha may therefore exert its luteolytic effect at a site after cholesterol transport to the mitochondria but before cholesterol side-chain cleavage.
Asunto(s)
Cuerpo Lúteo/metabolismo , Dinoprost/farmacología , Lipoproteínas/metabolismo , Aminoglutetimida/metabolismo , Animales , Bovinos , Células Cultivadas , Colesterol/metabolismo , Cuerpo Lúteo/citología , Cuerpo Lúteo/efectos de los fármacos , Depresión Química , Femenino , Hidroxicolesteroles/farmacología , Luteólisis/fisiología , Mitocondrias/metabolismo , Progesterona/biosíntesisRESUMEN
The identification of metabolites from the pyridylglutarimide 3-ethyl-3-(4-pyridyl)piperidine-2,6-dione (PG, Rogletimide) was achieved using liquid chromatography-mass spectrometry with a thermospray interface (LC-TSP-MS). The urinary metabolites include PG N-oxide, the products of 4- and 5-hydroxylation in the piperidine residue (4- and 5-hydroxy-PG) and a gamma-butyrolactone derived via terminal hydroxylation in the ethyl residue. In addition to the above metabolites, several products of glutarimide ring-opening could be detected in the plasma extracts after multiple-dose treatment. Thus LC-TSP-MS is potentially a simple and rapid technique in studies of drug metabolism for the important glutarimide class of drug.
Asunto(s)
Aminoglutetimida/análogos & derivados , Antineoplásicos/metabolismo , Aminoglutetimida/sangre , Aminoglutetimida/metabolismo , Aminoglutetimida/uso terapéutico , Aminoglutetimida/orina , Antineoplásicos/sangre , Antineoplásicos/uso terapéutico , Antineoplásicos/orina , Neoplasias de la Mama/tratamiento farmacológico , Cromatografía Líquida de Alta Presión , Femenino , Humanos , Espectroscopía de Resonancia Magnética , Espectrometría de Masas , Estándares de ReferenciaRESUMEN
The antiestrogen tamoxifen and the aromatase inhibitor aminoglutethimide show similar response rates when used in the endocrine management of advanced breast cancer. However, numerous clinical trials have demonstrated no increase in response rate from treatment with the drug combination of tamoxifen plus aminoglutethimide. We investigated the possibility of a pharmacokinetic interaction between these two drugs in six menopausal woman with breast cancer. All patients were investigated under three different conditions (termed phases A, B, and C). The steady state kinetics of tamoxifen were determined when administered alone (phase A) and after coadministration of aminoglutethimide for 6 weeks (phase B). In phase B, the pharmacokinetics for aminoglutethimide were determined and compared with these parameters after a tamoxifen washout of 6 weeks (phase C). The serum concentration of tamoxifen and most of its metabolites ([trans-1(4-beta-hydroxy-ethoxyphenyl)-1,2-diphenylbut-1-ene], 4-hydroxytamoxifen, 4-hydroxy-N-desmethyltamoxifen, N-desmethyltamoxifen, and N-desdimethyltamoxifen) were markedly reduced following aminoglutethimide administration, corresponding to an increase in tamoxifen clearance from 189-608 ml/min. The amount of most metabolites in serum increased relative to the amount of parent tamoxifen. These data are consistent with induction of tamoxifen metabolism during aminoglutethimide exposure. We found no effect of tamoxifen on aminoglutethimide pharmacokinetics or acetylation. We conclude that this aminoglutethimide-tamoxifen interaction should be taken into account when evaluating the clinical effect of this drug combination relative to monotherapy.
Asunto(s)
Aminoglutetimida/farmacología , Tamoxifeno/sangre , Acetilación , Anciano , Aminoglutetimida/metabolismo , Cortisona/análogos & derivados , Cortisona/farmacología , Interacciones Farmacológicas , Femenino , Glucuronatos/metabolismo , Humanos , Persona de Mediana Edad , Tamoxifeno/metabolismoRESUMEN
A 10-cm long alpha 1-acid glycoprotein column is used for the enantiomeric resolution of the clinically used racemic aminoglutethimide (+/- AG) and its acetylated metabolite (+/- AAG). A direct liquid chromatographic resolution of racemic aminoglutethimide and its acetylated metabolite is accomplished without any derivatizations. Maximum resolutions of 1.37 and 0.73 are obtained for the enantiomers of aminoglutethimide and its acetylated metabolite, respectively. The effect of the 2-propanol content in mobile phase on retention and enantioselectivity of aminoglutethimide and its acetylated metabolite is demonstrated. The variation of the separation factors (alpha) with pH in enantiomeric separation of aminoglutethimide is also shown.
Asunto(s)
Aminoglutetimida/análisis , Aminoglutetimida/metabolismo , Cromatografía Líquida de Alta Presión , Orosomucoide , EstereoisomerismoRESUMEN
A homologous series of 1-n-alkyl-derivatives of aminoglutethimide (AG) has been synthesised and tested for inhibitory activity towards the cholesterol side chain cleavage enzyme (desmolase) from bovine adrenals and human placental aromatase in an attempt to find a selective aromatase inhibitor. Activity against desmolase declined from an IC50 value of 30 microM for the parent drug to 220 microM for the n-propyl derivative but increased again thereafter. Against aromatase, activity was least for the methyl and ethyl derivatives and highest (IC50 = 1.6 microM) for the hexyl and octyl analogues. The optimal ratio IC50 (desmolase):IC50 aromatase of 44 was found for the n-propyl derivative, which was therefore selected for preliminary metabolism studies using rat and mouse liver microsomes and hepatocytes and in these species in vivo. There were parallels with AG, most notably in the analogous formation from the n-propyl derivative of an arylhydroxylamine in the mouse.
Asunto(s)
Aminoglutetimida/análogos & derivados , Inhibidores de la Aromatasa , Enzima de Desdoblamiento de la Cadena Lateral del Colesterol/antagonistas & inhibidores , Acetilación , Aminoglutetimida/metabolismo , Animales , Masculino , Ratas , Ratas Endogámicas , Relación Estructura-ActividadRESUMEN
1. Following administration of a single oral dose of 14C-aminoglutethimide to rats, guinea-pigs, rabbits and man, greater than 89% of the dose was excreted in urine and faeces within 72 h; dogs eliminated only 51% in this time. 2. Extensive metabolism occurred in all species, with N-acetylaminoglutethimide being the major metabolite except for dog and man. In the latter two species unchanged drug was the main product excreted. 3. A metabolite, 3-(4-acetamidophenyl)-3-(2-carboxamidoethyl)tetrahydrofuran-2-one, not previously found in human urine, was identified. 4. Chronic administration of aminoglutethimide to rats produced no detectable change in the excretory or metabolite patterns of the drug. However chronic administration of phenobarbitone decreased the urinary excretion of 14C over a 72 h period. 5. Residual (72 h) tissue levels of 14C were less than 1 microgram equivalent of 14C-aminoglutethimide/g tissue in the rat, guinea-pig and rabbit. Dog tissues retained a considerable quantity of 14C at this time.
Asunto(s)
Aminoglutetimida/farmacocinética , Aminoglutetimida/metabolismo , Animales , Radioisótopos de Carbono , Perros , Femenino , Cobayas , Humanos , Masculino , Conejos , Ratas , Factores Sexuales , Especificidad de la Especie , Distribución TisularRESUMEN
Aminoglutethimide (AG) is now an established agent for producing a 'medical adrenalectomy' in patients with breast cancer. A number of annoying symptoms can occur in some patients placed on this medication. It has been suggested that the expression of symptoms may be related to the ability of the patient to acetylate AG to N-acetyl aminoglutethimide (NAG). Using high-pressure liquid chromatography (HPLC), we examined blood levels of AG and NAG in patients with breast cancer and compared the levels to the expression and frequency of drug symptoms. 43% of patients examined were judged to be slow acetylators in that 92% of the drug remained unacetylated irrespective of the dose administered. There was no significant correlation between acetylator status (rapid vs. slow) and the frequency of drug symptoms noted. In contrast, there was a significant correlation between the level of AG itself and the frequency of symptoms. 80% of patients with blood levels exceeding 12 mg/l had drug-related symptoms while only 36% of patients with levels below 8 mg/l showed symptoms (chi 2 p less than 0.05). 67% of patients with NAG levels in excess of 4 mg/l had symptoms. These findings indicate the presence of slow and rapid acetylators of AG in a breast cancer population and the importance of determining blood levels of the drug to minimize the onset of drug-related symptoms in some patients without losing drug efficacy.
Asunto(s)
Aminoglutetimida/efectos adversos , Neoplasias de la Mama/tratamiento farmacológico , Aminoglutetimida/metabolismo , Neoplasias de la Mama/metabolismo , Cromatografía Líquida de Alta Presión , Femenino , Humanos , Urticaria/inducido químicamenteRESUMEN
We have compared the response of the N-methyl-N-nitrosourea-induced rat mammary tumor to various endocrine agents with response in patients with breast cancer. To do this, we have induced tumors in 228 animals (65% of intact rats developed tumors but only 14% of ovariectomized rats developed tumors). In intact rats, 4-hydroxyandrostenedione, tamoxifen, and a combination of tamoxifen, aminoglutethimide (AG), and danazol induced significant tumor regression (P less than 0.001, P = 0.01, P = 0.04, respectively), whereas danazol, AG, and trilostane were ineffective when used singly. Further investigation showed that the inactivity of AG in the rat was due to extensive acetylation of this compound. In order to mimic postmenopausal breast cancer, we ovariectomized rats after N-methyl-N-nitrosourea administration. In ovariectomized animals, AG was again ineffective in inducing tumor regression but 4-hydroxyandrostenedione was highly active when compared to controls (P = 0.002). Comparison with response of this model to endocrine therapy with response in patients indicates that this has good predictive capacity since it shows that agents which have minor activity in human breast cancer such as danazol and trilostane are inactive in the model. The intact rat model does not, however, predict whether a drug will be useful for pre- or postmenopausal patients. We recommend that before committing large numbers of patients to clinical trials on the basis of this model, the metabolism of new compounds should be compared in humans and rats.
Asunto(s)
Neoplasias de la Mama/terapia , Neoplasias Mamarias Experimentales/terapia , Aminoglutetimida/metabolismo , Androstenodiona/análogos & derivados , Androstenodiona/uso terapéutico , Animales , Protocolos de Quimioterapia Combinada Antineoplásica , Danazol/uso terapéutico , Dihidrotestosterona/análogos & derivados , Dihidrotestosterona/uso terapéutico , Femenino , Humanos , Neoplasias Mamarias Experimentales/tratamiento farmacológico , Menopausia , Metilnitrosourea , Ovariectomía , Ratas , Tamoxifeno/uso terapéuticoRESUMEN
Pyridoglutethimide [3-ethyl-3-(4-pyridyl)piperidine-2,6-dione] has been developed as an analogue of aminoglutethimide [3-(4-aminophenyl)-3-ethyl-piperidine-2,6-dione] possessing specific aromatase activity with potency comparable to aminoglutethimide. This study investigates the pharmacokinetics of pyridoglutethimide in the rat and the rabbit: the plasma half-life is 6 hr in the rat and 16.4 hr in the rabbit. The sole metabolite found in urine (rat) and plasma (rat and rabbit) is pyridoglutethimide N-oxide.
Asunto(s)
Aminoglutetimida/análogos & derivados , Antineoplásicos/metabolismo , Aminoglutetimida/metabolismo , Animales , Cromatografía en Capa Delgada , Femenino , Semivida , Humanos , Cinética , Masculino , Espectrometría de Masas , Conejos , Ratas , Ratas EndogámicasAsunto(s)
Aminoglutetimida/farmacología , Microsomas/enzimología , Aminoglutetimida/metabolismo , Aminoglutetimida/orina , Antipirina/metabolismo , Dexametasona/metabolismo , Digitoxina/metabolismo , Interacciones Farmacológicas , Activación Enzimática/efectos de los fármacos , Humanos , Cinética , Medroxiprogesterona/análogos & derivados , Medroxiprogesterona/metabolismo , Acetato de Medroxiprogesterona , Microsomas/efectos de los fármacos , Teofilina/metabolismo , Warfarina/metabolismoAsunto(s)
Aminoglutetimida/metabolismo , Aminoglutetimida/farmacología , Aminoglutetimida/uso terapéutico , Antineoplásicos/uso terapéutico , Neoplasias de la Mama/tratamiento farmacológico , Fenómenos Químicos , Química , Cumarinas/metabolismo , Dexametasona/metabolismo , Femenino , Hormonas/metabolismo , HumanosRESUMEN
Aminoglutethimide (AG) is a drug that inhibits several steps of steroidogenesis; it is used in post-menopausal advanced breast cancer. More recently it has been proposed as a hormone therapy in prostatic cancer. Clinical studies involving patients resistant to orchidectomy and estrogens have generally given poor objective results and a frequent subjective response. It is too early to predict the interest of AG in the hormone therapy of prostate cancer since the studies are too few and since it has been used very late in the evolution of cancer.
Asunto(s)
Aminoglutetimida/uso terapéutico , Neoplasias de la Próstata/tratamiento farmacológico , Glándulas Suprarrenales/metabolismo , Aminoglutetimida/metabolismo , Andrógenos/metabolismo , Evaluación de Medicamentos , Humanos , MasculinoRESUMEN
A case report of adrenocortical carcinoma is presented, and its natural history and treatment are discussed. Adrenocortical carcinoma is a rare malignant disease. The mean survival time for untreated patients is less than three months. The tumor is classified as functioning or nonfunctioning depending on biochemical and clinical evidence of steroid overproduction. Surgical resection of the tumor is the primary treatment. Chemotherapy is indicated for antitumor and antihormonal effects. Mitotane is a direct adrenolytic, and is the only drug currently available that has extended survival in patients with this disease. Its clinical usefulness is limited by its gastrointestinal and neurological toxicity. Aminoglutethimide inhibits steroid synthesis by blocking the conversion of cholesterol to pregnenolone. It has no antitumor effect in adrenocortical carcinoma, but is effective in relieving the signs and symptoms of excessive hormone production in functioning tumors. Both mitotane and aminoglutethimide have complex mechanisms of action. Their combined use in the treatment of adrenocortical carcinoma requires a complete understanding of their individual actions and awareness of the potential for additive effects, both therapeutic and toxic.
Asunto(s)
Neoplasias de la Corteza Suprarrenal/tratamiento farmacológico , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Neoplasias de la Corteza Suprarrenal/cirugía , Adulto , Aminoglutetimida/administración & dosificación , Aminoglutetimida/efectos adversos , Aminoglutetimida/metabolismo , Protocolos de Quimioterapia Combinada Antineoplásica/efectos adversos , Protocolos de Quimioterapia Combinada Antineoplásica/metabolismo , Femenino , Humanos , Cinética , Mitotano/administración & dosificación , Mitotano/efectos adversos , Mitotano/metabolismo , Esteroides/uso terapéuticoRESUMEN
The uptake of 14C-labeled aminoglutethimide into the brain was investigated in the rat after intracarotid injection according to the method of Oldendorf, as well as in cisternal cerebrospinal fluid obtained by suboccipital puncture after i.v. injection of the drug. The brain uptake index of aminoglutethimide after intracarotid injection was 30.7 + 2.4%. Cerebrospinal fluid/blood quotients after i.v. drug injection were 0.53 at 10 min and 0.26 at 60 min. The results of both methods clearly show that aminoglutethimide easily penetrates the blood brain barrier.